伊马替尼治疗晚期胃肠间质瘤的临床疗效分析

Analysis on the clinic curative effect of imatinib in treatment of advanced gastrointestinal stromal tumor

目的探讨伊马替尼治疗晚期胃肠间质瘤的临床疗效及胃肠间质瘤临床病理学特征间的疗效差异性。方法回顾性分析74例晚期胃肠间质瘤患者的临床资料,并根据其临床病理学特征分组,分别比较不同组间伊马替尼疗效的差异性,并记录治疗的毒副作用。结果根据Choi标准评价伊马替尼治疗晚期胃肠间质瘤12月后的疗效,有效率(response rate)RR为87.8%(65/74),疾病控制率为94.6%(70/74),不同转移病灶部位(P=0.001)的RR有显著性差异。主要不良反应有胃肠道反应,肝肾功能损害,白细胞减少,水肿、皮疹,对症治疗后症状均可缓解或消失。结论 (1)伊马替尼对晚期胃肠间质瘤有较好的疗效,不良反应轻微;(2)有效率可能与性别、年龄、危险度、原发部位无明显差异性,而与转移灶部位有显著差异。

Objective To explore the clinic curative effect of Imatinib in treatment of advanced gastrointestinal stromal tumor,and the difference of curative effect and clinic pathological features.Methods Retrospectively analyzed the clinic pathological date of 74 cases of advanced gastrointestinal stromal tumor,and all patients were divided into different groups according to the clinic pathological features,respectively compared the difference of the clinic curative effect of Imatinib among the different groups,and record its side effects.Results Evaluate the curative effect after treating with Imatinib for 12 months by Choi criteria,the response rate（RR） was 87.8%,and the disease control rate was 94.6%,the RR with different metastatic sites（P=0.001） were significantly different.The side effects mainly includes gastrointestinal reaction,liver and kidney function damage,leucopenia,edema,skin rash,and the symptoms can alleviate or disappear after symptomatic treatment.Conclusion Imatinib has good effect on advanced gastrointestinal stromal tumor,but it has mild adverse reactions;No significant difference were observed between the RR and sex,age,risk and primary sites,but with metastatic sites were significantly different.